Resnick Joshua 4
4 · PepGen Inc. · Filed Jun 22, 2026
Research Summary
AI-generated summary of this filing
PepGen (PEPG) Director Joshua Resnick Receives 34,000-Share Option Award
What Happened
Joshua Resnick, a member of PepGen's board of directors, received a derivative award covering 34,000 shares on June 18, 2026. The grant is reported at $0.00 per share (derivative), meaning no cash was paid by Resnick; this is a stock-based award (option/RSU-style instrument) rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-06-18; Form 4 filed: 2026-06-22 (filed four days after the reported transaction). This appears to exceed the typical two-business-day Form 4 window.
- Instrument: Derivative award covering 34,000 shares reported at $0.00 per share.
- Vesting: The award vests in full on the earlier of (i) the first anniversary of the grant or (ii) the next Annual Meeting; vesting stops if Resnick ceases to serve as a director unless the Board decides otherwise (Footnote F1).
- Beneficial ownership: Resnick holds the option for the benefit of RA Capital-managed vehicles (RA Capital Healthcare Fund, RA Capital Nexus Fund II, and a separately managed account) and disclaims beneficial ownership; any net cash or stock received upon exercise is turned over to the Adviser to offset advisory fees (Footnote F2).
- Shares owned after transaction: Not specified in the filing.
Context
This was a grant/award (not a market purchase or sale), so it does not signal a personal cash investment by the director. The filing indicates the award is held for institutional clients of RA Capital and Resnick disclaims beneficial ownership, meaning the economic benefit and voting/control implications differ from a direct personal holding.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1][F2]2026-06-18+34,000→ 34,000 totalExercise: $1.79Exp: 2036-06-17→ Common Stock (34,000 underlying)
Footnotes (2)
- [F1]This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.
- [F2]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.